2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, CML, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5066 Long-term outcomes update of mini-hyper-CVD plus inotuzumab ozogamicin with or without blinatumomab as frontline therapy for older adults with newly diagnosed Philadelphia Chromosome–Negative B-cell acute lymphoblastic leukemia

Georgio Medawar, MD, Elias Jabbour, MD2, Hannah Goulart, MD3, Nitin Jain, MD4, Farhad Ravandi, MD5, Tapan Kadia I, MD6, Naval Daver, MD7, Naveen Pemmaraju, MD8, William G. Wierda, MD, PhD9, Yesid Alvarado Valero, MD10, Gautam Borthakur, MD11, Jan A. Burger, MD, PhD12, Kelly Sharon Chien, MD13, Courtney DiNardo, MD, MSCE14, Alessandra Ferrajoli III, MD15, Guillermo Montalban-Bravo, MD16, Musa Yilmaz, MD17, Michael Andreeff, MD, PhD18, Steven Kornblau, MD19, Abhishek Maiti, MBBS20, Lucia Masarova, MD21, Maro Ohanian, DO22, Koichi Takahashi, MD,PhD23, Christina Simon24, Christopher Loiselle, BS25, Rebecca Garris26, Guillermo Garcia-Manero, MD27, Nicholas Short, MD28, Hagop Kantarjian, MD29
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
24 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
25 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
26 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
27 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
28 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
29 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Background

Older adults with B-cell acute lymphoblastic leukemia (B-ALL) have poor outcomes with a median (med) overall survival (OS) of 7 months (m). Incorporating CD22- and CD19-directed immunotherapy into an attenuated chemotherapy regimen for older adults was shown to be effective and safe. We now provide a long-term update on the response durability, late toxicities, and survival impact of adding inotuzumab ozogamicin (InO) with or without blinatumomab (Blina) to mini-hyper-CVD (mHCVD) in older patients (pts).

Methods

Eligible pts were ≥60 years (yrs) old with newly diagnosed Philadelphia–negative (Ph-neg) B-ALL, adequate organ function and ECOG performance status ≤3. Reduced-dose chemotherapy mHCVD (cyclophosphamide, dexamethasone, and vincristine with alternating methotrexate/cytarabine cycles (C)s) was given for up to 8 Cs, with CNS intrathecal prophylaxis and CD20-directed rituximab when indicated. InO was originally dosed once per C (1.3-1.8mg/m2 on day 3 of C1 and 0.8-1.3mg/m2 on day 3 of Cs 2-4) but was fractionated into lower weekly doses (0.6 mg/m2 on day 2 and 0.3 mg/m2 on day 8 of C1; 0.3 mg/m2 on day 2 and 8 of C2-4 capped at a 2.7 mg/m² cumulative dose) beginning with pt 50 in March 2017 to reduce hepatotoxic risk; from that point, 4 Cs of Blina replaced the final 4 mHCVD Cs, and the POMP (vincristine/prednisone/mercaptopurine/methotrexate) maintenance therapy was shortened with interspersed Blina Cs [1 C of Blina (total of 4) after every 3 POMP Cs]. Pts received 12 IT chemotherapy and ursodiol.

Results

Eighty-three pts (median age 67 yrs, range 60–88) were treated from Dec 2011 to Aug 2022; 49 pre- and 34 post-amendment, median age 69 and 67 yrs, respectively. Six pts were enrolled in complete remission (CR) (5/6 had positive measurable residual disease [MRD+]). TP53 mutations were present in 25/64 (39%), high-risk cytogenetics in 19/67 (28%) (12 hypodiploid, 4 tetraploid, 4 complex, 1 KMT2A rearranged), and CRLF2 rearrangement in 7/48 (14%) pts). Four pts (5%) had baseline CNS involvement. Among evaluable pts, 76/77 (99%) achieved a CR/CR with incomplete recovery (CR 69%), and flow-MRD negativity in 93% of evaluable pts; 75% achieved MRD-negativity after cycle 1. NGS-MRD negativity occurred in 16/17 (94%) pts; none of these 16 pts relapsed at a median follow-up (FU) of 37 m.

With a median FU of 118 m (144 m pre-amendment and 61 m post-amendment pts), the 6-yr RFS rate was 40% and OS rate was 42% for the whole cohort. The 6-yr RFS and OS rates were higher in the post-amendment cohort vs pre-amendment, at 52% vs 32% (p=0.5) and 52 vs 38% (p=0.48), respectively. At 60 m, the cumulative incidence of relapse was 9% in post-amendment and 17% in pre-amendment (p=0.3), with NRM rates of 33% and 37% (p=0.9), respectively. The 6-yr RFS and OS rates in pts 60-69 yrs were significantly higher than those ≥70 yrs, 55% vs 41% (p=0.04) and 51% vs 42% (p=0.02), respectively. In pts 60-69 yrs, the 6-yr RFS and OS for pts who received vs did not receive Blina were 55% vs 46% m (p=0.9) and 63% vs 53% m (p=0.9), respectively. In pts ≥ 70 yrs, 6-yr RFS and OS rates with or without Blina were 41% and 20% (p=0.5), and 41% and 20% (p=0.5), respectively.

A total of 13 (16%) pts had disease relapse at a median time of 14 m (3-60 m) from CR. Five pts (7%) underwent SCT in CR1, 4 for HR-genomics and 1 for persistent MRD+; 1 died in relapse after SCT, 2 died in CR (1 SCT-related complications,1 unknown), and 2 are alive in CR. One pt received CAR T-cell therapy for MRD relapse but relapsed 5 m later and died. There were 4 (5%) extramedullary-only relapses (1 CNS [32 m after CR],1 liver/epidural, 1 CNS [8 m after CR], and 1 paraspinal]. Secondary myeloid neoplasms emerged in 9 pts (11%, median age 71 yrs [64-87]) at a median of 33 m (3-66 m) from treatment, 5/8 carrying persistent TP53mut.  Grade 3 InO-related Veno-occlusive disease (VOD) occurred in 4 pts (5%), prompting InO discontinuation. Grade 3 Blina-related CNS events occurred in 7 pts (8%), none discontinued treatment. Forty-one pts died in CR (10 infectious complications, 4 VOD, 9 secondary myeloid neoplasms, 18 other [gunshot, cardiorenal syndrome, 2 solid malignancies,14 unknown).

Conclusion

mHCVD, InO +/- Blina results in durable remissions and meaningful long-term survival in older adults with Ph-negative B-ALL, supporting its ongoing use as a frontline option. However, excess NRM supports the need to develop chemotherapy-free regimens, which are currently being explored.

Georgio Medawar, MD: No relevant conflicts of interest to declare.